{"id":12873,"date":"2025-08-07T18:34:52","date_gmt":"2025-08-07T13:04:52","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=12873"},"modified":"2025-08-07T18:34:52","modified_gmt":"2025-08-07T13:04:52","slug":"morepen-laboratories-q1-results-highlights","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/quarterly-results\/morepen-laboratories-q1-results-highlights\/","title":{"rendered":"Morepen Laboratories Q1 Results Highlights: Net Profit Declines 70%, Expenses Rise by 0.9%"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

Morepen Laboratories [NSE: MOREPENLAB], a leading player in India\u2019s <\/span>pharmaceuticals sector<\/span><\/a>, reported its Q1 FY26 results on Wednesday, 6th August 2025. The company\u2019s performance showed a challenging quarter, marked by a significant drop in net profit and a slight decline in revenue. Despite these challenges, the company continues to operate in a sector that holds growth potential. Investors often track <\/span>Morepen Laboratories share price<\/span><\/a> to gauge the company\u2019s market performance, with the pharmaceuticals sector showing steady growth potential despite the current downturn.<\/span><\/p>\n

For Q1 FY26, Morepen Laboratories reported a 70.4% year-on-year decline in net profit, which came down to \u20b910.74 crore from \u20b936.2 crore in Q1 FY25. This decline was mainly due to lower revenue from operations, which saw a 6.6% fall, bringing it down to \u20b9425.23 crore compared to \u20b9455.21 crore last year.<\/span><\/p>\n

<\/span>Key Financial Results for Morepen Laboratories Q1 FY26:<\/span><\/b>\u00a0<\/span><\/span><\/h2>\n\n\n\n\n\n\n\n\n
Particulars<\/span><\/b>\u00a0<\/span><\/td>\nQ1 FY26 (\u20b9 Cr)<\/span><\/b>\u00a0<\/span><\/td>\nQ4 FY25 (\u20b9 Cr)<\/span><\/b>\u00a0<\/span><\/td>\nQ1 FY25 (\u20b9 Cr)<\/span><\/b>\u00a0<\/span><\/td>\nYoY Growth (%)<\/span><\/b>\u00a0<\/span><\/td>\nQoQ Growth (%)<\/span><\/b>\u00a0<\/span><\/td>\n<\/tr>\n
Total Income (\u20b9 Cr)<\/span>\u00a0<\/span><\/td>\n429.7<\/span>\u00a0<\/span><\/td>\n470.5<\/span>\u00a0<\/span><\/td>\n458.6<\/span>\u00a0<\/span><\/td>\n-6.3%<\/span>\u00a0<\/span><\/td>\n-8.7%<\/span>\u00a0<\/span><\/td>\n<\/tr>\n
Income from Operations (Net) (\u20b9 Cr)<\/span>\u00a0<\/span><\/td>\n425.2<\/span>\u00a0<\/span><\/td>\n465.9<\/span>\u00a0<\/span><\/td>\n455.2<\/span>\u00a0<\/span><\/td>\n-6.6%<\/span>\u00a0<\/span><\/td>\n-8.7%<\/span>\u00a0<\/span><\/td>\n<\/tr>\n
Net Profit (\u20b9 Cr)<\/span>\u00a0<\/span><\/td>\n10.7<\/span>\u00a0<\/span><\/td>\n20.3<\/span>\u00a0<\/span><\/td>\n36.2<\/span>\u00a0<\/span><\/td>\n-70.4%<\/span>\u00a0<\/span><\/td>\n-47.2%<\/span>\u00a0<\/span><\/td>\n<\/tr>\n
EPS Basic (\u20b9)<\/span>\u00a0<\/span><\/td>\n0.20<\/span>\u00a0<\/span><\/td>\n0.35<\/span>\u00a0<\/span><\/td>\n0.71<\/span>\u00a0<\/span><\/td>\n-71.8%<\/span>\u00a0<\/span><\/td>\n-42.9%<\/span>\u00a0<\/span><\/td>\n<\/tr>\n
EPS Diluted (\u20b9)<\/span>\u00a0<\/span><\/td>\n0.20<\/span>\u00a0<\/span><\/td>\n0.35<\/span>\u00a0<\/span><\/td>\n0.71<\/span>\u00a0<\/span><\/td>\n-71.8%<\/span>\u00a0<\/span><\/td>\n-42.9%<\/span>\u00a0<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n


\n\"\"
\n<\/a><\/p>\n